FDA Office of Hematology and Oncology Products is now Office of Oncologic Diseases

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Office of Hematology and Oncology Products at FDA has been renamed the Office of Oncologic Diseases—a move that includes an internal reorganization of divisions, as part of modernization plans approved in September 2019.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong

YOU MAY BE INTERESTED IN

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait. 
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login